Chih-Shiang Chang

Dr. Chih-Shiang Chang


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
KWKuo-Ching Wen
Kuo-Ching Wen
CCChih-Shiang Chang
Chih-Shiang Chang
YCYin-Chih Chien
Yin-Chih Chien
HWHsiao-Wen Wang
Hsiao-Wen Wang
WWWan-Chen Wu
Wan-Chen Wu
Hsiu-Mei ChiangHsiu-Mei Chiang
Hsiu-Mei Chiang
Melanin is responsible for skin color and plays a major role in defending against harmful external factors such as ultraviolet (UV) irradiation. Tyrosinase is responsible for the critical steps of melanogenesis, including the rate-limiting step of tyrosine hydroxylation. The mechanisms of action of skin hypopigmenting agents are thought to be based on the ability of a given agent to inhibit the activity of tyrosinase and, hence, down regulate melanin synthesis. Tyrosol and its glycoside, salidroside, are active components of Rhodiola rosea, and in our preliminary study we found that Rhodiola rosea extract inhibited melanogenesis. In this study, we examined the effects of tyrosol and its analogues on melanin synthesis. We found that treatment of B16F0 cells to tyrosol (1), 4-hydroxyphenylacetic acid (5), 3-hydroxyphenylacetic acid (6), 2-hydroxyphenylacetic acid (7), or salidroside (11) resulted in a reduction in melanin content and inhibition of tyrosinase activity as well as its expression. Tyrosol (1), 4-hydroxyphenylacetic acid (5) and 2-hydroxyphenylacetic acid (7) suppressed MC1R expression. Tyrosol (1), 4-hydroxyphenylacetic acid (5), 3-hydroxyphenylacetic acid (6), and 2-hydroxyphenylacetic acid (7) inhibited α-MSH induced TRP-1 expression, but salidroside (11) did not. All the compounds did not affect MITF and TRP-2 expression. Furthermore, we found that the cell viability of tyrosol (1), 4-hydroxyphenylacetic acid (5), 3-hydroxyphenylacetic acid (6), and 2-hydroxyphenylacetic acid (7) at concentrations below 4 mM and salidroside (11) at concentrations below 0.5 mM were higher than 90%. The compounds exhibited metal-coordinating interactions with copper ion in molecular docking with tyrosinase. Our results suggest that tyrosol, 4-hydroxyphenylacetic acid, 3-hydroxyphenylacetic acid, 2-hydroxyphenylacetic acid, and salidroside are potential hypopigmenting agents.

1 August 2016 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
CCChien-Yu Chen
Chien-Yu Chen
NLNai-Yu Liu
Nai-Yu Liu
HLHui-Chang Lin
Hui-Chang Lin
CLChih-Yu Lee
Chih-Yu Lee
Chin-Chuan HungChin-Chuan Hung
Chin-Chuan Hung
CCChih-Shiang Chang
Chih-Shiang Chang

1 January 2017 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
CCChien-Yu Chen
Chien-Yu Chen
CLChin-Min Lin
Chin-Min Lin
HLHui-Chang Lin
Hui-Chang Lin
CHChien-Fu Huang
Chien-Fu Huang
CLChih-Yu Lee
Chih-Yu Lee
CCChih-Shiang Chang
Chih-Shiang Chang

Verified
Journal Article
Open access
PDF file
JLJu-Fang Liu
Ju-Fang Liu
YHYuan-Li Huang
Yuan-Li Huang
WYWei-Hung Yang
Wei-Hung Yang
CCChih-Shiang Chang
Chih-Shiang Chang
CTChih-Hsin Tang
Chih-Hsin Tang
In this study, we investigated the anticancer effects of a new benzimidazole derivative, 1-benzyl-2-phenyl -benzimidazole (BPB), in human chondrosarcoma cells. BPB-mediated apoptosis was assessed by the MTT assay and flow cytometry analysis. The in vivo efficacy was examined in a JJ012 xenograft model. Here we found that BPB induced apoptosis in human chondrosarcoma cell lines (JJ012 and SW1353) but not in primary chondrocytes. BPB induced upregulation of Bax, Bad and Bak, downregulation of Bcl-2, Bid and Bcl-XL and dysfunction of mitochondria in chondrosarcoma. In addition, BPB also promoted cytosolic releases AIF and Endo G. Furthermore, it triggered extrinsic death receptor-dependent pathway, which was characterized by activating Fas, FADD and caspase-8. Most importantly, animal studies revealed a dramatic 40% reduction in tumor volume after 21 days of treatment. Thus, BPB may be a novel anticancer agent for the treatment of chondrosarcoma.

24 October 2021 in Biomedicines
Verified
Journal Article
Open access
PDF file
JGJing-Yan Gao
Jing-Yan Gao
CCChih-Shiang Chang
Chih-Shiang Chang
JLJin-Cherng Lien
Jin-Cherng Lien
TCTing-Wei Chen
Ting-Wei Chen
JHJing-Lan Hu
Jing-Lan Hu
翁W翁靖如 Weng
翁靖如 Weng
Trytanthrin, found in Ban-Lan-Gen, is a natural product containing an indoloquinazoline moiety and has been shown to possess anti-inflammatory and anti-viral activities. Chronic inflammation and hepatitis B are known to be associated with the progression of hepatocellular carcinoma (HCC). In this study, a series of tryptanthrin derivatives were synthesized to generate potent anti-tumor agents against HCC. This effort yielded two compounds, A1 and A6, that exhibited multi-fold higher cytotoxicity in HCC cells than the parent compound. Flow cytometric analysis demonstrated that A1 and A6 caused S-phase arrest and downregulated the expression of cyclin A1, B1, CDK2, and p-CDC2. In addition to inducing caspase-dependent apoptosis, A1 and A6 exhibited similar regulation of the phosphorylation or expression of multiple signaling targets, including Akt, NF-κB, and mitogen-activated protein kinases. The anti-tumor activities of A1 and A6 were also attributable to the generation of reactive oxygen species, accompanied by an increase in p-p53 levels. Therefore, A1 and A6 have potential clinical applications since they target diverse aspects of cancer cell growth in HCC.

5 April 2023 in Virus Research
Verified
Journal Article
Open access
WLWen-Wei Lin
Wen-Wei Lin
YHYi-Jung Huang
Yi-Jung Huang
YWYeng-Tseng Wang
Yeng-Tseng Wang
YLYun-Syuan Lin
Yun-Syuan Lin
NMNonsikelelo Mazibuko
Nonsikelelo Mazibuko
CCChih-Hung Chuang
Chih-Hung Chuang
• Compound 3, 8, and 9 were identified to inhibit the ZIKV NS2B-NS3 protease activity of ZIKV. • Compound 3, 8, and 9 inhibit ZIKV NS2B-NS3 protease activity in a non-competitive mode. • Compound 8 significantly delayed lethality and illness symptoms in a ZIKV-infected suckling mouse model. • Compound 8 is worth further investigation for use as a potential future therapeutic agent against ZIKV infection.